RespiQ, a Dutch healthtech startup, secures €4 million in capital. The goal of respiQ, which uses ground-breaking breath diagnostics technology to enhance the wellbeing of COPD patients, is furthered by this significant investment.
Mira Gleisberg, CEO of RespiQ, commented: “Receiving the EIC Pathfinder grant marks a significant milestone for our company and consortium, as it enables us to accelerate the development of our cutting-edge breath diagnostics device, bringing hope to thousands of COPD patients struggling to monitor their disease.”
Professor Mona Bafadhel, Chair of Respiratory Medicine and Director of the King’s Centre for Lung Health at King’s College London, said: “The impact of this funding will be potentially game-changing. Ways to diagnose onset of deterioration in COPD are urgently warranted. With a non-invasive test like a breath test, this could mean that in the future patients living with COPD will be able to safely monitor their condition without the need for a trip to hospital. As the clinical partner for this project, we look forward to the advancements this funding will allow our research to achieve for COPD patients in the future.”
The financing will enhance non-invasive remote patient monitoring by hastening the development and miniaturisation of RespiQ’s state-of-the-art breath diagnostics technology.
The company’s goal is to enhance COPD patients’ standard of life by developing a sensor device allowing for in-home, real-time patient monitoring. This technology has the potential to revolutionise the way COPD patients are treated through offering an early warning system for oncoming lung attacks.
COPD is a common lung disease affecting around 400 million people worldwide and is the third largest cause of death worldwide. COPD is the cause of 6% of all deaths worldwide.
RJ Schuurs, Partner at Antler, added: “We are delighted to have supported RespiQ from day zero of their growth journey and this prestigious funding grant is testament to their long-term growth potential. This is an outstanding founding team building a technology that could improve the lives of thousands of people around the world. We are very excited to see what RespiQ and their consortium partners can deliver in the coming years.”
A revolutionary AI-enhanced breath analysis sensor for real-time disease detection and treatment is being created by the Dutch start-up RespiQ. Their non-invasive, cost-effective health monitoring system will make it easy to use both at home and at the point of service.